TRDA at a glance
Entrada Therapeutics, Inc. (TRDA, SEC CIK 1689375) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as September 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Entrada Therapeutics, Inc. (TRDA) reported revenue of $25.4 million (down 87.9% from FY2024) and a net loss of $143.8 million. Diluted EPS was -$3.47.
- As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Entrada Therapeutics, Inc. (TRDA) shares worth $71.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by MPM BioVentures 2014, L.P. on September 9, 2026 of 28,837 shares at $7.13 per share.
- In the last 90 days, TRDA insiders reported 0 open-market purchases ($0) and 24 open-market sales ($7.2M) on Form 4, a net sale of $7.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $25.4M
- −87.9% vs prior year
- Insiders · 90 days
- 0 buys · 24 sells
- Net −$7.2M
- 13F holders
- 24 funds
- $71.8M · −1 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Collaboration revenue $0.9M, down $0.7M YoY from $1.6M
- Net loss $39.7M vs $44.1M YoY, operating loss $41.7M vs $47.1M
- ENTR-601-44 highest program spend at $6.2M, ENTR-601-45 increased to $4.5M
- Operating cash use $104.1M, marketable-securities maturities drove $124.9M investing inflow
- Cash, equivalents and securities $193.0M, funding expected into fourth quarter 2027; additional funding required
Risk Factors
- Newly added regulatory risk: October 2026 FDA orphan-drug designation for ENTR-601-45 may not deliver exclusivity or other benefits
- Most material regulatory update: June 2026 FDA draft guidance permits one pivotal trial with confirmatory evidence, but additional trials remain possible
- Compliance risk: BIOSECURE Act Section 851 could disrupt China-based suppliers and foreign contract manufacturers
- Operational risk: Vertex controls VX-670 development, with interim GALILEO Phase 1/2 results expected in second half of 2026
- Financial risk: Cash, equivalents and marketable securities fund operations into fourth quarter 2027, but substantial going-concern doubt remains
AI summary of the TRDA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Corporate updates included alongside quarterly results
Item EX-99.1: Item EX-99.1
- Q3 2026 results show net loss $39.7M, or $0.94 per share, versus $44.1M, or $1.06, in Q3 2025
- Cash, equivalents and marketable securities fell to $193.0M from $295.7M, supporting operations into Q4 2027
Item 7.01: Regulation FD Disclosure
- Positive first-cohort results for ENTR-601-45 in Phase 1/2 ELEVATE-45-201 study
- Clinical program targets Duchenne muscular dystrophy, a key development milestone for Entrada
Item 8.01: Other Events
- Cohort 1 showed dystrophin increase of 0.10% versus placebo decline of 0.02%, supporting biological activity at 5 mg/kg
- Exon skipping rose 0.15% versus placebo decline of 0.04%, strengthening ENTR-601-45’s mechanistic evidence
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026 announced August 5, 2026
- Financial details and corporate updates contained in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q2 2026 net loss $42.8M, or $1.01 per share, versus $43.1M and $1.04 in Q2 2025
- Cash, equivalents and marketable securities $223.0M, down from $295.7M, funding operations into Q3 2027
AI summaries of TRDA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TRDA
Don't miss the next TRDA filing
- Alerts as it files. A push when TRDA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TRDA, by share count.
- Ask anything. An AI agent that reads every TRDA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| MPM BioVentures 2014, L.P. | Sell | Sep 9, 2026 | 28,837 | $7.13 |
| MPM BIOVENTURES 2018, L.P. | Sell | Sep 9, 2026 | 28,837 | $7.13 |
| MPM BioVentures 2014, L.P. | Sell | Sep 8, 2026 | 192,500 | $7.41 |
| MPM BIOVENTURES 2018, L.P. | Sell | Sep 8, 2026 | 192,500 | $7.41 |
| MPM BIOVENTURES 2018, L.P. | Sell | Sep 4, 2026 | 38,500 | $7.11 |
| MPM BioVentures 2014, L.P. | Sell | Sep 4, 2026 | 38,500 | $7.11 |
| MPM BioVentures 2014, L.P. | Sell | Sep 3, 2026 | 32,263 | $7.17 |
| MPM BIOVENTURES 2018, L.P. | Sell | Sep 3, 2026 | 32,263 | $7.17 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $129.0M | $210.8M | $25.4M |
| Operating Income | -$3.2M | $47.0M | -$157.9M |
| Net Income | -$6.7M | $65.6M | -$143.8M |
| Op. Margin | -2.5% | 22.3% | -621.1% |
| Net Margin | -5.2% | 31.1% | -565.5% |
| Balance Sheet | |||
| Total Assets | - | $526.3M | $377.4M |
| Equity | - | $428.7M | $306.1M |
| ROE | - | 15.3% | -47.0% |
| Per Share | |||
| EPS | - | $1.68 | $-3.47 |
| Cash Flow | |||
| Operating CF | $139.8M | -$41.6M | -$128.5M |
| CapEx | - | $3.2M | $1.0M |
Source: XBRL data in Entrada Therapeutics, Inc. (TRDA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate TRDA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 24 | $71.8M |
| Q2 2026 | 25 | $80.8M |
| Q1 2026 | 26 | $91.7M |
| Q4 2025 | 23 | $73.6M |
| Q3 2025 | 23 | $48.3M |
| Q2 2025 | 22 | $61.3M |
| Q1 2025 | 20 | $43.1M |
| Q4 2024 | 17 | $76.8M |
- BlackRock+653.8K (+25%)
- Morgan Stanley+194.6K (+102%)
- D.E. Shaw & Co+124.8K (+385%)
- Goldman Sachs Group+120.8K (+68%)
- Bank of America Corp+92.6K (+160%)
- Millennium Management−419.4K (-55%)
- T. Rowe Price Group−417.8K (-77%)
- AQR Capital Management−75.7K (-11%)
- Dimensional Fund Advisors−32.1K (-9%)
- Ameriprise Financial−27.5K (-39%)
- FMR LLC (Fidelity)−2.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 180 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TRDA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 14, 2026 | - | Analysis | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
TRDA SEC filings: frequently asked questions
Are TRDA insiders buying or selling?
In the last 90 days, Entrada Therapeutics, Inc. (TRDA) officers, directors and 10% owners reported no open-market purchases and 24 open-market sales worth $7.2 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TRDA stock?
As of September 30, 2026, the largest Entrada Therapeutics, Inc. (TRDA) holders among the 13F filers tracked by SignalX were BlackRock ($20.6 million), Merck & Co. ($11.0 million), Vanguard Capital Management LLC ($8.1 million), AQR Capital Management ($4.0 million), State Street Corp ($3.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TRDA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Entrada Therapeutics, Inc. (TRDA) reported revenue of $25.4 million (down 87.9% from FY2024) and a net loss of $143.8 million. Diluted EPS was -$3.47. The figures come from the XBRL data in the 10-K.
What did TRDA report in its latest 8-K?
Entrada Therapeutics, Inc. (TRDA) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.
What are the latest TRDA SEC filings?
Entrada Therapeutics, Inc. (TRDA) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on September 9, 2026.
What is TRDA's SEC CIK number?
Entrada Therapeutics, Inc. (TRDA)'s SEC Central Index Key (CIK) is 1689375. EDGAR lists every TRDA filing under that number.
Ask anything about TRDA
The research agent reads TRDA's filings, financials, insider trades and 13F holders, then answers with sources.